Korean Journal of Clinical Pharmacy最新文献_第9页

A Survey on Willingness to Accept Community Pharmacist’s Consultation Service Regarding Well-dying 社区药师临终关怀咨询服务接受意愿调查

Korean Journal of Clinical Pharmacy Pub Date : 2021-06-30 DOI: 10.24304/kjcp.2021.31.2.145

Ki Ung Shin, Hyunjoo Sohn

引用次数: 0

Clinical Effects of Zinc Supplementation in Patients Hospitalized with COVID-19: A Systematic Review and Meta-analysis 补充锌对COVID-19住院患者的临床效果:系统回顾和meta分析

Korean Journal of Clinical Pharmacy Pub Date : 2021-06-30 DOI: 10.24304/kjcp.2021.31.2.136

Hyewon Park, S. Lee, Sook Hee An

引用次数: 2

Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case 用集总法研究生理药代动力学(PBPK)与室室药代动力学模型的相容性:在伏立康唑案例中的应用

Korean Journal of Clinical Pharmacy Pub Date : 2021-06-30 DOI: 10.24304/kjcp.2021.31.2.125

Hyo-Jeong Ryu, Won-Ho Kang, J. Chae, Hwi‐yeol Yun

引用次数: 0

Awareness on expiration date of repackaged prescription medications and pulverization of solid pills: A questionnaire study 重新包装的处方药和固体丸粉碎的有效期意识:一项问卷调查研究

Korean Journal of Clinical Pharmacy Pub Date : 2021-06-30 DOI: 10.24304/kjcp.2021.31.2.96

So Yeon Kim, Y. Choi, Hyunjoo Sohn

引用次数: 0

Exploring the Perception on Drug Utilization Review System and DUR Modernization Pilot Project: A Qualitative Study Using Focus Group Interviews 对药品利用审评制度及DUR现代化试点项目的认知探索:焦点小组访谈的定性研究

Korean Journal of Clinical Pharmacy Pub Date : 2021-06-30 DOI: 10.24304/kjcp.2021.31.2.104

Sungho Bea, Ha-Lim Jeon, D. Yoon, Ahhyung Choi, Hyesung Lee, Ju-Young Shin

引用次数: 1

Utilization of Preventive Therapy in Korean Migraine Patients 预防治疗在韩国偏头痛患者中的应用

Korean Journal of Clinical Pharmacy Pub Date : 2021-03-31 DOI: 10.24304/KJCP.2021.31.1.35

Yewon Kim, Susin Park, Eonjeong Kim, N. Je

{"title":"Utilization of Preventive Therapy in Korean Migraine Patients","authors":"Yewon Kim, Susin Park, Eonjeong Kim, N. Je","doi":"10.24304/KJCP.2021.31.1.35","DOIUrl":"https://doi.org/10.24304/KJCP.2021.31.1.35","url":null,"abstract":"Background: Migraine is a common neurological disorder that affects the quality of life and causes several health problems. Preventive migraine treatment can reduce migraine frequency, headache severity, and health care costs. This study aimed to estimate the utilization of migraine preventive therapy and associated factors in eligible patients. Methods: We studied 534 patients with migraine who were eligible for migraine preventive therapy using 2017 National Patient Sample (NPS) data from the Health Insurance Review and Assessment Service (HIRA). We estimated the migraine days by calculating the monthly average number of defined daily dose (DDD) of migraine-specific acute drug. Patients with a monthly average number of DDD of 4 or more were considered as subjects for preventive treatment. Chi-square test and multiple logistic regression analysis were used to determine the association between the preventive therapy and the influencing variables. Results: Less than half of the eligible patients for prophylaxis (n=234, 43.8%) were prescribed preventive therapy. Multiple logistic regression results show that migraine preventive therapy was influenced by age, the type of migraine, and some comorbidities. Patients over the age of 50 tend to receive less prophylactic treatment than under the age of 40. On the other hand, migraine patients with epilepsy or depression were more likely to receive preventive therapy. Sumatriptan was the most preferred medication for acute treatment, and propranolol was the most commonly prescribed drug for prevention. Conclusions: More than half of the patients who were candidates for migraine prophylaxis were not receiving suitable preventive treatment. Positive factors affecting the use of migraine prevention were the presence of comorbidities such as epilepsy and depression.","PeriodicalId":17901,"journal":{"name":"Korean Journal of Clinical Pharmacy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91319728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Clinical and Laboratory Features of Pediatric Patients with COVID-19: Systematic Review and Meta-analysis 小儿COVID-19患者的临床和实验室特征:系统评价和荟萃分析

Korean Journal of Clinical Pharmacy Pub Date : 2020-12-31 DOI: 10.24304/kjcp.2020.30.4.270

H. Yoon, Young-ah Cho, Jeong Yee, H. Gwak, Ji Min Han

引用次数: 1

Analysis of Prevalence of Anemia according to Severity of Atopic Dermatitis 特应性皮炎严重程度对贫血患病率的分析

Korean Journal of Clinical Pharmacy Pub Date : 2020-12-31 DOI: 10.24304/kjcp.2020.30.4.264

D. Yun, Ji-Eun Chang, K. Rhew

{"title":"Analysis of Prevalence of Anemia according to Severity of Atopic Dermatitis","authors":"D. Yun, Ji-Eun Chang, K. Rhew","doi":"10.24304/kjcp.2020.30.4.264","DOIUrl":"https://doi.org/10.24304/kjcp.2020.30.4.264","url":null,"abstract":"Background: Inflammatory diseases can increase the prevalence of anemia. Recent studies confirmed that the prevalence of anemia is increased by atopic dermatitis (AD), a chronic inflammatory disease. Therefore, we aimed to elucidate the correlation between AD severity and prevalence of anemia. Methods: We used data of pediatric patients from the Health Insurance Review and Assessment Service (HIRA-PPS-2016). We included pediatric patients ( < 18 years) with AD diagnosis who were prescribed medications for AD. We applied a propensity score method with inverse probability of treatment weighting (IPTW) adjusting for differences in prevalence of confounders and performed IPTW logistic regression to evaluate associations between the anemia and severity of AD. Results: In total, 91,501 patients (mild AD: 47,054 patients; moderate-to-severe AD: 44,447 patients) < 18 years who were prescribed drugs for AD were analyzed. Analysis of the probability of patients with mild AD and prevalence of anemia as a reference revealed an odds ratio (OR) of 1.159 (95% CI, 1.109-1.212; p < 0.001) in moderate-to-severe AD patients, indicating a correlation between anemia prevalence and AD severity. Subgroup analysis according to gender, age group, and type of health insurance revealed there was an association between AD severity and anemia except in patients equal or older than 7 years. Conclusion: The prevalence of anemia increased with AD severity despite adjusting for confounding factors. Our results support the hypothesis that AD can cause anemia, and anemia prevalence could be increased in severe AD patients. Further studies are needed to establish a pathological basis.","PeriodicalId":17901,"journal":{"name":"Korean Journal of Clinical Pharmacy","volume":"69 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84184092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Usage Patterns and Outcomes by Dual Type Calcium Channel Blockers in Patients with Chronic Kidney Disease 双型钙通道阻滞剂在慢性肾病患者中的使用模式和疗效比较

Korean Journal of Clinical Pharmacy Pub Date : 2020-12-31 DOI: 10.24304/kjcp.2020.30.4.259

M. Oh, H. Ahn, Sunmi Choi, H. La

{"title":"Comparison of Usage Patterns and Outcomes by Dual Type Calcium Channel Blockers in Patients with Chronic Kidney Disease","authors":"M. Oh, H. Ahn, Sunmi Choi, H. La","doi":"10.24304/kjcp.2020.30.4.259","DOIUrl":"https://doi.org/10.24304/kjcp.2020.30.4.259","url":null,"abstract":"Background: Dual-type calcium channel blockers (CCBs), such as efonidipine and cilnidipine, are renoprotective drugs that reportedly reduce proteinuria by dilating afferent and efferent arterioles of the glomerulus. However, studies comparing the effect of dual-type CCB on proteinuria have not been conducted. Therefore, we aimed to compare the effect of dual-type CCB (efonidipine and cilnidipine) usage patterns in hypertensive patients with chronic kidney disease (CKD). Methods: This single-center, retrospective study included 53 patients with CKD who 1) initiated efonidipine or cilnidipine treatment while on a renin-angiotensin system inhibitor and 2) had received efonidipine or cilnidipine for at least one year. We compared usage patterns between the efonidipine and cilnidipine groups during the one-year period and analyzed the following outcomes: urinary protein-to-creatinine ratio, blood pressure, and serum creatinine. Results: The study included 25 patients in the efonidipine group and 28 patients in the cilnidipine group. In both groups, blood pressure and urinary protein-to-creatinine ratios tended to decrease; however, the change during each interval was not significant. Conclusions: In patients with CKD who were on renin-angiotensin system inhibitor therapy, the addition of a dual-type CCB (i.e., efonidipine or cilnidipine) tended to reduce proteinuria; however, the change during each interval was not significant.","PeriodicalId":17901,"journal":{"name":"Korean Journal of Clinical Pharmacy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78734320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinson’s Disease: A Scoping Review 非帕金森病患者使用普拉克索/罗匹尼罗相关的冲动控制障碍:范围综述

Korean Journal of Clinical Pharmacy Pub Date : 2020-12-31 DOI: 10.24304/kjcp.2020.30.4.250

Tae hyun Jeong, Seoung Min Suh, H. Song, Nakyung Jeon

引用次数: 0